JNJ 63871860

Drug Profile

JNJ 63871860

Alternative Names: E coli bioconjugate vaccine - GSK/Janssen; Expec 4v Conjugate; ExPEC vaccine - GSK/Janssen; ExPEC4V; Extra-intestinal pathogenic Escherichia coli vaccine - GSK/Janssen; JNJ-1860; JNJ-63871860; JNJ-860/EcoXyn-4V

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlycoVaxyn
  • Developer GlycoVaxyn; Janssen Pharmaceuticals
  • Class DNA vaccines; Escherichia coli vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Escherichia coli infections; Urinary tract infections

Most Recent Events

  • 17 Apr 2018 Janssen Research & Development plans a phase II trial for Healthy volunteers in USA , (NCT03500679)
  • 01 Nov 2017 Johnson and Johnson announces intention to submit NDA and MAA to US FDA and EMA for Bacterial infection in 2021 (Johnson and Johnson pipeline, October 2017)
  • 01 Aug 2016 Janssen Pharmaceutical completes a phase I trial in Escherichia coli infections (Prevention, In volunteers) in Japan (IM) (NCT02748967)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top